The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial: a new frontier for statins?

The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) Trial tested the hypothesis that intensive lowering of cholesterol with atorvastatin (80 mg/day) initiated 24-96 h after an acute coronary syndrome would, over 4 months, reduce the incidence of the composite endpoint of death...

Descripción completa

Detalles Bibliográficos
Autores principales: Waters, David, Schwartz, Gregory G, Olsson, Anders G
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2001
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59635/
https://www.ncbi.nlm.nih.gov/pubmed/11806782
http://dx.doi.org/10.1186/cvm-2-3-111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59635/
https://www.ncbi.nlm.nih.gov/pubmed/11806782
http://dx.doi.org/10.1186/cvm-2-3-111

Ejemplares similares